Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $35.9 million.

  • C4 Therapeutics' Total Current Liabilities fell 1697.27% to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year decrease of 1697.27%. This contributed to the annual value of $45.2 million for FY2024, which is 563.77% up from last year.
  • As of Q3 2025, C4 Therapeutics' Total Current Liabilities stood at $35.9 million, which was down 1697.27% from $44.5 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Total Current Liabilities peaked at $55.0 million during Q1 2024, and registered a low of $30.3 million during Q3 2023.
  • Over the past 5 years, C4 Therapeutics' median Total Current Liabilities value was $44.5 million (recorded in 2022), while the average stood at $44.4 million.
  • As far as peak fluctuations go, C4 Therapeutics' Total Current Liabilities tumbled by 3312.79% in 2023, and later skyrocketed by 4301.81% in 2024.
  • Quarter analysis of 5 years shows C4 Therapeutics' Total Current Liabilities stood at $51.2 million in 2021, then dropped by 13.07% to $44.5 million in 2022, then fell by 4.0% to $42.8 million in 2023, then increased by 5.64% to $45.2 million in 2024, then decreased by 20.44% to $35.9 million in 2025.
  • Its Total Current Liabilities was $35.9 million in Q3 2025, compared to $44.5 million in Q2 2025 and $40.8 million in Q1 2025.